United States was COSCIENS Biopharma’s largest region in fiscal 2025, bringing in $4.60M of $7.50M (61%).
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Ireland | — | — | — | — | |||
| United States | $8.60M | $3.42M | $6.69M | $4.60M | |||
| Germany | $4.56M | $3.56M | $1.36M | $2.38M | |||
| China | $1.33M | — | — | — | |||
| United Kingdom | — | — | $976.00K | $457.00K | |||
| Columbia | — | — | $300.00K | — | |||
| British Virgin Islands | — | — | — | — | |||
| Other | $83.00K | $164.00K | $260.00K | $59.00K | |||
| Singapore | — | — | — | — | |||
| Total | $14.57M | $7.14M | $9.59M | $7.50M |
COSCIENS Biopharma brought in $7.50M from its four regions in fiscal 2025, the year ended December 31, 2025. COSCIENS Biopharma regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $9.59M. United States was the largest at $4.60M (61.4%), ahead of Germany at $2.38M (31.7%) and United Kingdom at $457.00K (6.1%). The remaining region, Other, brought in $59.00K.
Compared with fiscal 2024, Germany grew fastest, up 74.9% to $2.38M, while United Kingdom fell the most, down 53.2% to $457.00K.
COSCIENS Biopharma began breaking out United Kingdom in fiscal 2024, when it brought in $976.00K. COSCIENS Biopharma stopped reporting China ($1.33M in fiscal 2022) and Columbia ($300.00K in fiscal 2024) as separate regions.
Active Ingredient was COSCIENS Biopharma’s largest segment in fiscal 2025, bringing in $7.04M of $7.50M (94%).
| Segments [axis] | FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Active Ingredient | $14.57M | $7.14M | $8.49M | $7.04M | ||
| Switzerland | — | — | — | — | ||
| Biopharmaceutical | — | — | $1.10M | $461.00K | ||
| Denmark | — | — | — | — | ||
| Ireland | — | — | — | — | ||
| Other | — | — | — | — | ||
| Total | $14.57M | $7.14M | $9.59M | $7.50M |
COSCIENS Biopharma brought in $7.50M from its two segments in fiscal 2025, the year ended December 31, 2025. That was down 21.8% from $9.59M in fiscal 2024. Active Ingredient was the largest at $7.04M (93.9%), ahead of Biopharmaceutical at $461.00K (6.1%).
Compared with fiscal 2024, Active Ingredient fell 17.1% to $7.04M and Biopharmaceutical fell 57.9% to $461.00K.
COSCIENS Biopharma began breaking out Biopharmaceutical in fiscal 2024, when it brought in $1.10M.
Active Ingredients was COSCIENS Biopharma’s largest revenue line in fiscal 2025, bringing in $7.04M of $7.50M (94%).
| Products and services [axis] | FY 2019 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Active Ingredients | $14.57M | $7.14M | $8.49M | $7.04M | |
| Biopharmaceutical | — | — | $1.10M | $461.00K | |
| Novo Supply Agreements | — | — | — | — | |
| Novo Supply Agreement | — | — | — | — | |
| License Strongbridge Agreement | — | — | — | — | |
| Royalties Strongbridge Agreement | — | — | — | — | |
| Total | $14.57M | $7.14M | $9.59M | $7.50M |
COSCIENS Biopharma brought in $7.50M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 21.8% from $9.59M in fiscal 2024. Active Ingredients was the largest at $7.04M (93.9%), ahead of Biopharmaceutical at $461.00K (6.1%).
Compared with fiscal 2024, Active Ingredients fell 17.1% to $7.04M and Biopharmaceutical fell 57.9% to $461.00K.
COSCIENS Biopharma began breaking out Biopharmaceutical in fiscal 2024, when it brought in $1.10M.
COSCIENS Biopharma (CSCIF) reports its revenue by geography, by segments [axis] and by products and services [axis]. In fiscal 2025, United States was its largest region, bringing in $4.60M (61.4% of the total), followed by Germany at $2.38M (31.7%).
United States was COSCIENS Biopharma's largest region in fiscal 2025, bringing in $4.60M, or 61.4% of the $7.50M total across its four regions.
Active Ingredient was COSCIENS Biopharma's largest segment in fiscal 2025, bringing in $7.04M, or 93.9% of the $7.50M total across its two segments.
Active Ingredients was COSCIENS Biopharma's largest revenue line in fiscal 2025, bringing in $7.04M, or 93.9% of the $7.50M total across its two revenue lines.
Every figure comes from COSCIENS Biopharma's annual financial filings, as reported. Each line keeps the name COSCIENS Biopharma gives it, and years follow its fiscal calendar.
COSCIENS Biopharma's revenue by geography goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.